Latest News

Dermatologists share vitiligo breakthrough news with patients


 

Two big questions are how long people will need to continue using ruxolitinib cream and whether depigmentation will recur if people stop using it.

Another aspect of therapy being studied is whether the cream will be even more effective in combination with other treatments.

“The main combination we think about is ruxolitinib with phototherapy – a light treatment – because light could stimulate those pigment cells,” Dr. Rosmarin said,

He noted that light therapy was included in phase 2 testing and that patients did respond. “What we need and what’s planned is a larger study looking at the combination to see whether it is synergistic or not. The longer patients use the cream, the more benefit we see,” Dr. Rosmarin said.

Dr. Desai has served as an investigator and/or consultant to several companies, including Incyte. Dr. Rosmarin has received honoraria as a consultant and has received research support from Incyte, and has served as a paid speaker for Incyte, as well as other companies.. Dr. Chovatiya has served as an advisory board member, consultant, and/or investigator for companies that include Incyte.

Pages

Recommended Reading

When is MRI useful in the management of congenital melanocytic nevi?
MDedge Family Medicine
Insurance coverage for vitiligo varies widely in the U.S., analysis finds
MDedge Family Medicine
Ruxolitinib cream meets primary endpoints in phase 3 vitiligo trial
MDedge Family Medicine
An 11-year-old female presented with skin discoloration on her back
MDedge Family Medicine
Photoprotection strategies for melasma are increasing
MDedge Family Medicine
Synthetic, botanical agents emerging as promising melasma treatments
MDedge Family Medicine
PIH in patients with dark skin responds to laser treatment: Small case series
MDedge Family Medicine
FDA cautions against using OTC products to remove skin spots, moles
MDedge Family Medicine
Ruxolitinib found to benefit adolescents with vitiligo up to one year
MDedge Family Medicine
FDA approves topical ruxolitinib for nonsegmental vitiligo
MDedge Family Medicine